Breast Cancer Imaging with Novel PET Tracers

PET Clinics

Volumn 4, Issue 4, 2009, Pages 371-380

  Mankoff, David A ^a   Lee, Jean H ^b   Eubank, William B ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VA Puget Sound   (United States)

Author keywords

Biomarker; Breast cancer; Imaging; PET; PET CT; Response

Indexed keywords

ACETIC ACID C 11; BEVACIZUMAB; CAPECITABINE; CHOLINE C 11; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; GELDANAMYCIN; GLYCOPROTEIN P; INTEGRIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; SIGMA OPIATE RECEPTOR; SOMATOSTATIN RECEPTOR; TAXANE DERIVATIVE; TRACER; TRASTUZUMAB; VINCA ALKALOID; WATER O 15;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG RESPONSE; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR VASCULARIZATION;

EID: 75349097480     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2009.10.003     Document Type: Review

References (106)

1. Doyle D.M., and Miller K.D. Development of new targeted therapies for breast cancer. Breast Cancer 15 1 (2008) 49-56
2. Kaklamani V., and O'Regan R.M. New targeted therapies in breast cancer. Semin Oncol 31 2 Suppl 4 (2004) 20-25
3. Olopade O.I., Grushko T.A., Nanda R., et al. Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res 14 24 (2008) 7988-7999
4. Benard F., and Turcotte E. Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography. Breast Cancer Res 7 4 (2005) 153-162
5. Lee J.H., Rosen E.L., and Mankoff D.A. The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 1-overview, detection, and staging. J Nucl Med 50 (2009) 569-581
6. Lee J.H., Rosen E.L., and Mankoff D.A. The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 2-response to therapy, other indications, and future directions. J Nucl Med 50 5 (2009) 738-748
7. Kelloff G.J., Krohn K.A., Larson S.M., et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 11 22 (2005) 7967-7985
8. Mankoff D.A., O'Sullivan F., Barlow W.E., et al. Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy. Acad Radiol 14 4 (2007) 398-405
9. Weber W.A. Positron emission tomography as an imaging biomarker. J Clin Oncol 24 20 (2006) 3282-3292
10. Jain R.K. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19 4 Suppl 3 (2005) 7-16
11. Hayes D.F., Miller K., and Sledge G. Angiogenesis as targeted breast cancer therapy. Breast 16 Suppl 2 (2007) S17-S19
12. Miller J.C., Pien H.H., Sahani D., et al. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 97 3 (2005) 172-187
13. Kety S.S. Basic principles for the quantitative estimation of regional cerebral blood flow. Res Publ Assoc Res Nerv Ment Dis 63 (1985) 1-7
14. Wilson C.B., Lammertsma A.A., McKenzie C.G., et al. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and non-invasive dynamic method. Cancer Res 52 (1992) 1592-1597
15. 2 positron emission tomography measurements of blood flow in patients with intra-abdominal cancers. Clin Cancer Res 9 17 (2003) 6350-6356
16. Mankoff D.A., Dunnwald L.K., Gralow J.R., et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 44 11 (2003) 1806-1814
17. Dunnwald L.K., Gralow J.R., Ellis G.K., et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 26 27 (2008) 4449-5726
18. 15O-labeled water-measured blood flow. J Nucl Med 49 4 (2008) 517-523
19. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med 45 11 (2004) 1829-1837
20. Zasadny K.R., Tatsumi M., and Wahl R.L. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging 30 2 (2003) 274-280
21. Eby P.R., Partridge S.C., White S.W., et al. Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer. Acad Radiol 15 10 (2008) 1246-1254
22. Schirner M., Menrad A., Stephens A., et al. Molecular imaging of tumor angiogenesis. Ann N Y Acad Sci 1014 (2004) 67-75
23. Charnley N., Donaldson S., and Price P. Imaging angiogenesis. Methods Mol Biol 467 (2009) 25-51
24. 18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 12 13 (2006) 3942-3949
25. 18F-Galacto-RGD PET. J Nucl Med 49 2 (2008) 255-259
26. 18F-AH111585 in breast cancer patients. J Nucl Med 49 6 (2008) 879-886
27. 18F-FDG PET study. Nucl Med Commun 28 10 (2007) 789-797
28. Mankoff D.A., Dunnwald L.K., Gralow J.R., et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 43 4 (2002) 500-509
29. Semple S.I., Gilbert F.J., Redpath T.W., et al. The relationship between vascular and metabolic characteristics of primary breast tumours. Eur Radiol 14 11 (2004) 2038-2045
30. Miles K.A., and Williams R.E. Warburg revisited: imaging tumour blood flow and metabolism. Cancer Imaging 8 (2008) 81-86
31. Mankoff D.A., Dunnwald L.K., Partridge S.C., et al. Blood flow-metabolism mismatch: good for the tumor, bad for the patient. Clin Cancer Res 15 17 (2009) 5294-5296
32. Schelbert H.R. PET contributions to understanding normal and abnormal cardiac perfusion and metabolism. Ann Biomed Eng 28 8 (2000) 922-929
33. Aboagye E.O., and Price P.M. Use of positron emission tomography in anticancer drug development. Invest New Drugs 21 2 (2003) 169-181
34. Saleem A., Aboagye E.O., Matthews J.C., et al. Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. Cancer Chemother Pharmacol 61 5 (2008) 865-873
35. Aboagye E.O., Price P.M., and Jones T. In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography. Drug Discov Today 6 6 (2001) 293-302
36. Kaye S.B. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr Opin Oncol 10 Suppl 1 (1998) S15-S19
37. Fojo T., and Coley H.M. The role of efflux pumps in drug-resistant metastatic breast cancer: new insights and treatment strategies. Clin Breast Cancer 7 10 (2007) 749-756
38. Piwnica-Worms D., Chiu M.L., Budding M., et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53 5 (1993) 977-984
39. Ciarmiello A., Vecchio S.D., Silvestro P., et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 16 5 (1998) 1677-1683
40. Kostakoglu L., Ruacan S., Ergun E.L., et al. Influence of the heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer. J Nucl Med 39 6 (1998) 1021-1026
41. Sciuto R., Pasqualoni R., Bergomi S., et al. Prognostic value of (99m)Tc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy. J Nucl Med 43 6 (2002) 745-751
42. Travaini L.L., Baio S.M., Cremonesi M., et al. Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy response. Breast 16 3 (2007) 262-270
43. Mankoff D.A., Dunnwald L.K., Gralow J.R., et al. [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow. Nucl Med Biol 29 7 (2002) 719-727
44. Elsinga P.H., Hendrikse N.H., Bart J., et al. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des 10 13 (2004) 1493-1503
45. Hendrikse N.H., de Vries E.G., Eriks-Fluks L., et al. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res 59 10 (1999) 2411-2416
46. 11C]verapamil kinetics in human tissues. Eur J Clin Pharmacol 56 11 (2001) 827-829
47. Sasongko L., Link J.M., Muzi M., et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 77 6 (2005) 503-514
48. 11C-verapamil in the brain: studies of healthy humans. J Nucl Med 50 8 (2009) 1267-1275
49. 18F]fluoropaclitaxel. Nucl Med Biol 34 7 (2007) 823-831
50. 18F-paclitaxel in nonhuman primates. J Nucl Med 44 (2003) 1330-1339
51. 18F-Fluoropaclitaxel and PET. J Nucl Med 47 12 (2006) 1995-1999
52. Gangloff A., Hsueh W.A., Kesner A.L., et al. Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J Nucl Med 46 11 (2005) 1866-1871
53. 18F-fluorocyclophosphamide in mice bearing human breast cancer xenografts. J Nucl Med 48 12 (2007) 2021-2027
54. 18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers. Nucl Med Biol 31 8 (2004) 1033-1041
55. Jordan V.C., and Brodie A.M. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72 1 (2007) 7-25
56. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
57. Osborne C.K., Yochmowitz M.G., Knight III W.A., et al. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46 Suppl 12 (1980) 2884-2888
58. Mankoff D.A., Link J.M., Linden H.M., et al. Tumor receptor imaging. J Nucl Med 49 Suppl 2 (2008) 149S-163S
59. Katzenellenbogen J. The pharmacology of steroid radiopharmaceuticals: specific and non-specific binding and uptake selectivity. In: Nunn A. (Ed). Radiopharmaceuticals: chemistry and pharmacology (1992), Marcel Dekker, New York 297-331
60. Katzenellenbogen J.A., Welch M.J., and Dehdashti F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res 17 (1997) 1573-1576
61. Katzenellenbogen J.A. Designing steroid receptor-based radiotracers to image breast and prostate tumors. J Nucl Med 36 Suppl 6 (1995) 8S-13S
62. Mintun M.A., Welch M.J., Siegel B.A., et al. Breast cancer: PET imaging of estrogen receptors. Radiology 169 1 (1988) 45-48
63. Peterson L.M., Mankoff D.A., Lawton T.J., et al. Quantitative imaging of estrogen receptor expression of breast cancer with PET and [F-18′-fluorestradiol. J Nucl Med 49 3 (2008) 367-74
64. Dehdashti F., Mortimer J.E., Siegel B.A., et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36 10 (1995) 1766-1774
65. Linden H.M., Stekhova S.A., Link J.M., et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24 18 (2006) 2793-2799
66. Mortimer J.E., Dehdashti F., Siegel B.A., et al. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19 11 (2001) 2797-2803
67. Mezi S., Primi F., Orsi E., et al. Somatostatin receptor scintigraphy in metastatic breast cancer patients. Oncol Rep 13 1 (2005) 31-35
68. Van Den Bossche B., Van Belle S., De Winter F., et al. Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scintigraphy. J Nucl Med 47 1 (2006) 6-13
69. Tu Z., Xu J., Jones L.A., et al. Fluorine-18-labeled benzamide analogues for imaging the sigma2 receptor status of solid tumors with positron emission tomography. J Med Chem 50 14 (2007) 3194-3204
70. Mach R.H., Huang Y., Buchheimer N., et al. [(18)F]N-(4′-fluorobenzyl)-4-(3-bromophenyl) acetamide for imaging the sigma receptor status of tumors: comparison with [(18)F]FDG, and [(125)I]IUDR. Nucl Med Biol 28 4 (2001) 451-458
71. 18F]FBFPA): a potential fluorine-18 labeled PET radiotracer for imaging sigma-1 receptors in the CNS. Synapse 58 4 (2005) 267-274
72. Wheeler K.T., Wang L.M., Wallen C.A., et al. Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer 82 6 (2000) 1223-1232
73. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25 33 (2007) 5287-5312
74. Smith-Jones P.M., Solit D., Afroze F., et al. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 47 5 (2006) 793-796
75. de Korte M.A., de Vries E.G., Lub-de Hooge M.N., et al. (111)Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 43 14 (2007) 2046-2051
76. Perik P.J., Lub-De Hooge M.N., Gietema J.A., et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 24 15 (2006) 2276-2282
77. 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 50 6 (2009) 974-981
78. 18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 24 34 (2006) 5366-5372
79. 18F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18 (2000) 1689-1695
80. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18 (2000) 1676-1688
81. Jansson T., Westlin J.E., Ahlstrom H., et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?. J Clin Oncol 13 6 (1995) 1470-1477
82. Ishiwata K., Enomoto K., Sasaki T., et al. A feasibility study on L-[1-carbon-11]tyrosine and L-[methyl-carbon-11]methionine to assess liver protein synthesis by PET. J Nucl Med 37 2 (1996) 279-285
83. Glunde K., Jacobs M.A., and Bhujwalla Z.M. Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn 6 6 (2006) 821-829
84. Bolan P.J., Nelson M.T., Yee D., et al. Imaging in breast cancer: magnetic resonance spectroscopy. Breast Cancer Res 7 4 (2005) 149-152
85. Stanwell P., and Mountford C. In vivo proton MR spectroscopy of the breast. Radiographics 27 Suppl 1 (2007) S253-S266
86. Meisamy S., Bolan P.J., Baker E.H., et al. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy-a pilot study at 4 T. Radiology 233 2 (2004) 424-431
87. 18F]FDG PET in clinical oncology. Lancet Oncol 8 9 (2007) 822-830
88. Lupu R., and Menendez J.A. Targeting fatty acid synthase in breast and endometrial cancer: an alternative to selective estrogen receptor modulators?. Endocrinology 147 9 (2006) 4056-4066
89. Powles T., Murray I., Brock C., et al. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 51 6 (2007) 1511-1520 [discussion: 1520-1]
90. Yu E.Y., and Mankoff D.A. Positron emission tomography imaging as a cancer biomarker. Expert Rev Mol Diagn 7 5 (2007) 659-672
91. 11C]Choline as a potential PET marker for imaging of breast cancer athymic mice. Nucl Med Biol 29 8 (2002) 803-807
92. Tannock I.F. Cell proliferation. In: Tannock I.F., and Hill R.P. (Eds). The basic science of oncology (1992), McGraw-Hill, New York 154-177
93. Cleaver J.E. Thymidine metabolism and cell kinetics. Front Biol 6 (1967) 43-100
94. Pinder S.E., Wencyk P., Sibbering D.M., et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 71 (1995) 146-149
95. Mankoff D.A., Shields A.F., and Krohn K.A. PET imaging of cellular proliferation. Radiol Clin North Am 43 1 (2005) 153-167
96. Shields A.F., Grierson J.R., Dohmen B.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4 11 (1998) 1334-1336
97. Been L.B., Elsinga P.H., de Vries J., et al. Positron emission tomography in patients with breast cancer using (18)F-3′-deoxy-3′-fluoro-l-thymidine ((18)F-FLT)-a pilot study. Eur J Surg Oncol 32 1 (2006) 39-43
98. 18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34 9 (2007) 1339-1347
99. Pio B.S., Park C.K., Pietras R., et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8 1 (2006) 36-42
100. 18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 31 5 (2004) 720-724
101. Hockenbery D. Defining apoptosis. Am J Pathol 146 1 (1995) 16-19
102. Blankenberg F., Ohtsuki K., and Strauss H.W. Dying a thousand deaths. Radionuclide imaging of apoptosis. Q J Nucl Med 43 2 (1999) 170-176
103. van de Wiele C., Lahorte C., Vermeersch H., et al. Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography. J Clin Oncol 21 18 (2003) 3483-3487
104. Schoenberger J., Bauer J., Moosbauer J., et al. Innovative strategies in in vivo apoptosis imaging. Curr Med Chem 15 2 (2008) 187-194
105. 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 46 4 (2005) 658-666
106. Tait J.F., Smith C., and Blankenberg F.G. Structural requirements for in vivo detection of cell death with 99mTc-annexin V. J Nucl Med 46 5 (2005) 807-815